

From: [REDACTED] [REDACTED]
Sent: 10 June 2008 09:31
To: Jeremy Powell
Subject: Febuxostat for Hyperuricaemia

Dear Jeremy

Please find below the answers from the Royal College of Pathologists perspective to the questions raised by NICE around the hyperuricaemia document.

.

The document is very comprehensive and well considered.

I. Do you consider that all of the relevant evidence has been taken into account?

Yes

II. Do you consider that the summaries of clinical and cost effectiveness are reasonable interpretations of the evidence, and that the preliminary views on the resource impact and implications for the NHS are appropriate?

Yes

III. Do you consider that the provisional recommendations of the Appraisal Committee are sound and constitute a suitable basis for the preparation of guidance to the NHS?

Yes

IV. Are there any equality related issues that need special consideration that are not covered in the ACD?

No

Regards

[REDACTED]

Delivered via MessageLabs
